


Sep 5<sup>th</sup>, 2015

#### ANIMAL CARE AND USE STATEMENT

As the corresponding author of the three manuscripts entitled "Pro- *versus* anti-stenotic capacities of type-I *versus* type-II human iPS-derived endothelial cells", I declare that all procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of National Center for Global Health and Medicine, Tokyo, Japan (Authorization No. 15014). The animals were acclimatized to laboratory conditions ( $23 \pm 3^{\circ}\text{C}$ , 12 h/12 h light/dark,  $55 \pm 15\%$  humidity, ad libitum access to food and water) prior to experimentation. The animal protocol was designed to minimize pain or discomfort to the animals by intraperitoneally administering the mixture of hydrochloric acid medetomidine (0.3mg/kg), midazolam (4mg/kg) and butorphanol tartrate (5mg/kg) using 26 gauge needles before operations.



Kumiko Saeki, M.D., Ph.D.

Director, Division of Stem Cell Therapy,

Department of Disease Control,

Research Institute, National Center for Global Health and Medicine

1-21-1 Toyama Shinjuku-ku Tokyo 162-8655, Japan

Phone: 81-3-3202-7181 ext.2882

FAX: 81-3-3202-7364

e-mail saeki@ri.ncgm.go.jp